Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

STROMALIGN

Financiado

Cerrado

Mechanisms and Targeting Stromal Contribution to Tumour Invasion and Metastasis

Angiogenesis inhibition has proven to be a successful anti-cancer therapeutic approach and anti-angiogenic therapies are currently approved as standard therapy in several types of cancer for their clinically validated beneficial e... ver más

31/05/2017

INSTITUT CATALA D'...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-05-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSTITUT CATALA D'ONCOLOGIA

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HOSTRESPONSE Host molecular and cellular responses to anti cancer drug tr... 1M€ Cerrado

ALTANGIOTARGET Understanding tumour resistance Receptors and signalling pa... 162K€ Cerrado

SAF2010-15661 SEÑALIZACION POR PI3K EN ANGIOGENESIS; UNA NUEVA DIANA TERAP... 145K€ Cerrado

BMDCS IN CANCER The impact of bone marrow derived cells on tumor growth and... 100K€ Cerrado

SAF2012-36575 NUEVAS DIANAS EN ANGIOGENESIS TUMORAL PARA BLOQUEAR LA REVAS... 193K€ Cerrado

SAF2015-70820-ERC PREDICCION DE LA RESPUESTA A LOS FARMACOS ANTIANGIOGENICOS:... 60K€ Cerrado

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Angiogenesis inhibition has proven to be a successful anti-cancer therapeutic approach and anti-angiogenic therapies are currently approved as standard therapy in several types of cancer for their clinically validated beneficial extension of overall survival, progression-free survival and/or time-to-progression in these cancer patients. Nevertheless, in preclinical mouse models of cancer, although these therapies also show significant anti-tumour effects and overall survival benefit, these therapies are also triggering increased tumour local invasion, with more distant dissemination and emergence of metastasis (overall tumour malignization). The clinical relevance of this malignization effect in patients that are currently being treated with antiangiogenic drugs still remains elusive, but the frequent tumour relapses and acquired resistance to therapy in some patients strongly suggests this insidious event should be exhaustively evaluated. In this sense, many laboratories are rapidly advancing in the study of the molecular players and signalling pathways implicated in this event, although an important limitation of all these approaches is that they are all based on Tumour-centered studies of the causes of malignization and are not taking into account the Tumour Stroma contribution to tumour invasion and metastasis. Thus, we postulate that the tumour stroma indeed plays a critical role in malignization after anti-angiogenic therapies and its specific mechanisms should be determined in order to target these stromal components to impede tumour malignization after antiangiogenic therapies. STROMALIGN is a groundbreaking project designed to overcome these current limitations from a novel perspective: instead of focusing on the genetically instable and highly adaptive tumour cell component, we rather postulate that the tumour stroma plays a critical role in malignization after anti-angiogenic therapies and its targeting could offer significant advantages of less adaptation/resistance, and broader applicability to several different tumour types. Thus, we will initially dissect the mechanisms of stromal contribution to this malignization effect, followed by pharmacological targeting this event in transgenic and recently developed Tumorgraft mouse models of cancer, and later on applying this knowledge to the clinical setting in samples from two approved clinical studies with anti-angiogenic therapies currently ongoing at our Hospital. By starting at the biology of animal models and later on validating these findings in the clinical setting we will tackle this current biomedical challenge by finding new stromal targets of malignancy that will ultimately benefit anti-angiogenic treated patients in the clinic.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores